Dear Friends,
I hope you are enjoying your summer! The MMRF’s first six months of this year have
been incredibly exciting. We are making unprecedented advances in accelerating
precision medicine for all patients, and I’m pleased to share that progress with you.
Our MMRF CoMMpass Study SM continues to drive this momentum. The insights we
are gaining from CoMMpass are advancing progress in many ways — from analyzing
why some patients have a better response to standard treatments to understanding
the right treatment path for patients with even the rarest of subtypes. Every piece of
data is invaluable.
Because of these successes, we’ve committed to strengthening the CoMMpass data
set by using it in new and innovative ways.
To that end, we have launched four groundbreaking initiatives that leverage our
unique Precision Medicine Model:
The MMRF CureCloud™ will house patient information and build upon
CoMMpass — which is already the largest genomics data set of any cancer.
This will allow patients to directly share their data with the MMRF to
accelerate cutting-edge research.
The MMRF Immunotherapy Initiative is investing $15 million to speed
the ever-expanding role of immunotherapy as a treatment for myeloma.
Our goal is to aggregate immunology data the way we aggregated genomic
data with our CoMMpass Study — leading to improved immune treatments.
The MMRF Answer Fund uses CoMMpass data combined with other data
sets to answer critical questions posed by myeloma researchers as well as
the patient community.
A LETTER
FROM
PAUL
GIUSTI
The MMRF Prevention Project is the first-ever research effort dedicated
to using our data for early detection and prevention of multiple myeloma.
What does this mean for patients? It means that we are moving toward a future
where we will have enough data so that each and every patient will know how to
precisely treat his or her specific type of myeloma.
We are encouraged by the promise of these initiatives and look forward to the new
insights they will generate in the months to come. Our work is driven by powerful
synergies between the patients who share their data, the researchers who drive
discoveries, and the physicians who put it all into practice. By working together,
we will unlock the key to a cure for every patient.
Warmly,
Paul Giusti
President and Chief Executive Officer